

## IRIDOID AND PHENOLIC GLYCOSIDES FROM *HARPAGOPHYTUM PROCUMBENS*

JOHANN F. W. BURGER, E. VINCENT BRANDT and DANEEL FERREIRA

Department of Chemistry, University of the Orange Free State, P.O. Box 339, Bloemfontein, 9300 Republic of South Africa

(Revised received 26 August 1986)

**Key Word Index**—*Harpagophytum procumbens*; Pedaliaceae; iridoid and phenolic glycosides; synthesis.

**Abstract**—A novel bioside,  $\beta$ -(3',4'-dihydroxyphenyl)ethyl- $O$ - $\alpha$ -L-rhamnopyranosyl(1  $\rightarrow$  3)- $\beta$ -D-glucopyranoside, was obtained from the secondary roots of *Harpagophytum procumbens*. It is accompanied by the known iridoid glucosides harpagoside, procumbide, and its 6'- $O$ - $p$ -coumaroyl ester, and phenolic glycosides, acteoside and isoacteoside, the latter pair being obtained from *H. procumbens* for the first time. The structures of these metabolites were differentiated by high resolution NMR studies, while that of the bioside is additionally supported by synthesis.

### INTRODUCTION

The utilization of *Harpagophytum procumbens* DC. (devil's claw), indigenous to the Kalahari Desert and Namibian Steppes of Southern Africa, as an anti-arthritis and general detoxifying remedy in the folk medicine [1, 2] of the native Africans of Namibia, initiated numerous chemical [3–5] and pharmacological [6, 7] investigations of the constituents of its secondary roots. Our re-investigation was directed mainly at the phenolic contents.

### RESULTS AND DISCUSSION


The acetone extract of the dried secondary roots afforded the known iridoid glucosides, harpagoside [8–10], procumbide [11–14] and 6'- $O$ - $p$ -coumaroylprocumbide [15], and phenolic glycosides, acteoside 1 [16–20] (= verbascoside [19] = kusagin [21]) and isoacteoside 3 [18, 22]. The latter two metabolites were obtained from *H. procumbens* for the first time and were identified by means of  $^1\text{H}$  NMR studies [cf. 18, 20, 22] at 500 MHz of their respective methyl ether acetates 2 and 4 (Table 1). Allocation of carbon signals was effected by  $^1\text{H}$ - $^{13}\text{C}$  heteronuclear correlations at 300 MHz (Table 2).

These compounds are accompanied by the novel bioside,  $\beta$ -(3',4'-dihydroxyphenyl)ethyl- $O$ - $\alpha$ -L-rhamnopyranosyl(1  $\rightarrow$  3)- $\beta$ -D-glucopyranoside 6 ( $\text{C}_{20}\text{H}_{30}\text{O}_{12}$ ), which was identified as methyl ether acetate 7 by means of spectroscopic methods. 80 MHz  $^1\text{H}$  NMR spectra of the bioside 6 revealed a strong resemblance to those of acteoside and isoacteoside lacking, however, the *trans*-caffeoyl moiety.  $^1\text{H}$  NMR data (Table 1) at 300 MHz of the methyl ether acetate 7 confirmed an  $\alpha$ -L-rhamnopyranosyl ( $\delta$ 4.79,  $J$  = 1.5 Hz, anomeric H;  $\delta$ 1.11,  $d$ ,  $J$  = 6.3 Hz, 6'-Me) and  $\beta$ -D-glucopyranosyl unit ( $\delta$ 4.38,  $d$ ,  $J$  = 8.0 Hz, anomeric H). Linkage of the rhamnosyl fragment to C-3 of the glucosyl moiety is defined by the chemical shift of H-3 ( $\delta$ 3.76,  $t$ ,  $J$  = 9.5 Hz) to higher field than those at the remaining *O*-acylated glycosidic C-atoms ( $\delta$ 5.13–4.96). Non-equivalence of the  $\alpha$ -methylene protons ( $\delta$ 3.61 and 4.08, both  $dt$ ,  $J$  = 7.0, 9.5 Hz) of the phenethyl unit, results from their proximity to the C-1

chiral centre and the exoanomeric effect [cf. 18].

The close structural relationship between the bioside 6, acteoside 1, and isoacteoside 3 was demonstrated by mild alkaline hydrolysis of the methyl ether of isoacteoside 5 which afforded methyl-(3,4-di- $O$ -methyl)caffeate and the methyl ether acetate 7 of the bioside following acetylation of the aqueous residue. Their co-existence in *H. procumbens* presumably reflects the biosynthetic formation of acteoside and isoacteoside from the bioside, while the established [23] physiological activity of the former pair may contribute to the claimed medicinal properties of the root extract.

Final proof for the position of linkage of the 3,4-dimethoxyphenethyl and  $\alpha$ -L-rhamnopyranosyl entities to the central glucopyranosyl unit in bioside 6 was provided by synthesis (Scheme 1). Protection of the 1-, 2-, 4- and 6-hydroxyl groups of  $\alpha$ -D-glucopyranose 8 afforded the di- $O$ -isopropylidene derivative 9 [24] via ring contraction. Benzoylation afforded the 3- $O$ -benzyl analogue 10 [25, 26] which was transformed into an anomeric mixture (45%  $\alpha$ : 55%  $\beta$ ) of the tetra- $O$ -acetylglucopyranoside 11 following successive cleavage with acidic methanol [27]



- 1  $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{H}$ ,  $\text{R}^2 = t$ -caffeoyl
- 2  $\text{R}^1 = \text{R}^3 = \text{Ac}$ ,  $\text{R}^4 = \text{Me}$ ,  $\text{R}^2 = t$ -di- $O$ -methylcaffeoyl
- 3  $\text{R}^1 = \text{R}^2 = \text{R}^4 = \text{H}$ ,  $\text{R}^3 = t$ -caffeoyl
- 4  $\text{R}^1 = \text{R}^2 = \text{Ac}$ ,  $\text{R}^4 = \text{Me}$ ,  $\text{R}^3 = t$ -di- $O$ -methylcaffeoyl
- 5  $\text{R}^1 = \text{R}^2 = \text{H}$ ,  $\text{R}^4 = \text{Me}$ ,  $\text{R}^3 = t$ -di- $O$ -methylcaffeoyl
- 6  $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{R}^4 = \text{H}$
- 7  $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{Ac}$ ,  $\text{R}^4 = \text{Me}$

Table 1.  $^1\text{H}$  NMR peaks (ppm) of phenolic glycoside methyl ether acetates 2,\* 4\* and 7† in  $\text{CDCl}_3$ . Splitting patterns and  $J$  values (Hz) are given in parentheses

	H	Acteoside 2	Isoacteoside 4	Bioside 7
Glucosyl	1	4.37 ( <i>d</i> , 8.0)	4.39 ( <i>d</i> , 8.0)	4.38 ( <i>d</i> , 8.0)
	2	5.04 ( <i>dd</i> , 8.0, 9.5)	5.05 ( <i>dd</i> , 8.0, 9.5)	5.01 ( <i>dd</i> , 8.0, 9.5)
	3	3.83–3.73 ( <i>m</i> , overlapping OMe)	3.77 ( <i>t</i> , 9.5)	3.76 ( <i>t</i> , 9.5)
	4	5.18 ( <i>t</i> , 9.5)	5.12 ( <i>t</i> , 9.5)	5.06 ( <i>t</i> , 9.5)
	5	3.60 ( <i>dq</i> , 2.5, 10.0)	3.60 ( <i>dq</i> , 2.5, 10.0)	3.54 ( <i>dq</i> , 2.5, 10.0)
	6	4.15 ( <i>dd</i> , 4.5, 12.5)	4.29 ( <i>dd</i> , 2.5, 12.5)	4.21 ( <i>dd</i> , 4.5, 12.5)
Rhamnosyl		4.11 ( <i>dd</i> , 3.0, 12.5)	4.24 ( <i>dd</i> , 4.5, 12.5)	4.09 ( <i>dd</i> , 2.5, 12.5)
	1'	4.81 ( <i>d</i> , 2.0)	4.79 ( <i>d</i> , 2.0)	4.79 ( <i>d</i> , 1.5)
	2'	5.02 ( <i>dd</i> , 2.0, 3.3)	5.05 ( <i>dd</i> , 2.0, 3.3)	5.08–5.03 ( <i>m</i> )
	3'	5.08 ( <i>dd</i> , 3.3, 10.0)	5.08 ( <i>dd</i> , 3.3, 10.0)	5.08–5.03 ( <i>m</i> )
	4'	4.90 ( <i>t</i> , 10.0)	4.89 ( <i>t</i> , 10.0)	4.97 ( <i>t</i> , 9.5)
	5'	3.89–3.83 ( <i>m</i> )	3.88–3.81 ( <i>m</i> )	3.88–3.80 ( <i>m</i> )
Phenethyl	6'-Me	1.02 ( <i>d</i> , 6.3)	1.12 ( <i>d</i> , 6.3)	1.11 ( <i>d</i> , 6.3)
	2"	6.69 ( <i>d</i> , 1.5)	6.70 ( <i>d</i> , 1.5)	6.73 ( <i>d</i> , 1.5)
	5"	6.74 ( <i>d</i> , 8.0)	6.73 ( <i>d</i> , 8.0)	6.79 ( <i>d</i> , 8.0)
	6"	6.68 ( <i>dd</i> , 1.5, 8.0)	6.69 ( <i>dd</i> , 1.5, 8.0)	6.72 ( <i>dd</i> , 1.5, 8.0)
	$\alpha$	4.04 ( <i>dt</i> , 7.0, 9.5)	4.06 ( <i>dt</i> , 7.0, 9.5)	4.08 ( <i>dt</i> , 7.0, 9.5)
		3.58 ( <i>dt</i> , 7.0, 9.5)	3.62 ( <i>dt</i> , 7.0, 9.5)	3.61 ( <i>dt</i> , 7.0, 9.5)
<i>r</i> -Caffeoyl	$\beta$	2.78 ( <i>t</i> , 7.0)	2.81 ( <i>t</i> , 7.0)	2.82 ( <i>t</i> , 6.8)
	2'''	6.97 ( <i>d</i> , 1.5)	6.99 ( <i>d</i> , 1.5)	
	5'''	6.81 ( <i>d</i> , 8.0)	6.84 ( <i>d</i> , 8.0)	
	6'''	7.04 ( <i>dd</i> , 1.5, 8.0)	7.06 ( <i>dd</i> , 1.5, 8.0)	
	$\alpha$	6.22 ( <i>d</i> , 16.0)	6.21 ( <i>d</i> , 16.0)	
	$\beta$	7.60 ( <i>d</i> , 16.0)	7.63 ( <i>d</i> , 16.0)	
OMe		3.86, 3.85, 3.84, 3.80 (each <i>s</i> )	3.90, 3.89, 3.84, 3.80 (each <i>s</i> )	3.89, 3.85 (each <i>s</i> )
OAc		2.04, 2.03, 1.94, 1.88, 1.81 (each <i>s</i> )	2.10, 2.08, 1.998, 1.995, 1.93 (each <i>s</i> )	2.19, 2.05, 1.99, 1.98, 1.92 ( $\times 2$ ) (each <i>s</i> )

\* 500 MHz.

† 300 MHz.

and acetylation. Due to the anomeric effect [28, 29], treatment of 11 with hydrogen bromide in acetic acid [30] afforded the 3-*O*-benzyl-1-bromo- $\alpha$ -D-glucopyranoside 12 which was immediately etherified with 3,4-dimethoxyphenethyl alcohol by a standard Koenigs-Knorr type reaction [31] to give the  $\beta$ -D-glucoside 13 ( $\delta$ 4.38, *d*,  $J$  = 8.0 Hz, H-1). Debenzilation of the latter followed by condensation with the 1-bromo- $\alpha$ -L-rhamnopyranoside† 15 and subsequent acetylation, afforded the bioside 7, identical to the corresponding derivative of the natural product.

#### EXPERIMENTAL

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded at 80, 300 and 500 MHz in  $\text{CDCl}_3$  and acetone- $d_6$  with TMS as reference. CD spectra were determined in MeOH. Media used for the separation of components were: Whatman No. 3 for PC, DC-Plastikfolien Kieselgel 60 F<sub>254</sub> 0.25 mm for TLC and Kieselgel PF<sub>254</sub> (1 mm, 20  $\times$  20 cm) for prep. TLC. TLC bands were located under UV and/or  $\text{H}_2\text{SO}_4$ -HCHO (40:1) spray reagent.

† Prepared by successive acetylation (acetic anhydride-pyridine) and bromination (HBr-acetic acid) of  $\alpha$ -L-rhamnopyranoside [30].

Prep. TLC bands were stripped with  $\text{Me}_2\text{CO}$  and those from PC with 70% aq. EtOH. Methylations were performed with excess  $\text{CH}_3\text{N}_2$  over 48 hr at  $-15^\circ$  and acetylations in  $\text{Ac}_2\text{O}$ -pyridine. Analyses were performed by Analytische Laboratorien, Fritz-Pregl-Strasse 24, 5270 Gummersbach 1 Elbach, West Germany.

*Extractions and fractionation of iridoid and phenolic glycosides.* The finely powdered root slices (1 kg) was de-waxed with *n*-hexane (1  $\times$  3 l, 12 hr) and successively extracted with ether (1  $\times$  3 l, 12 hr), EtOAc (1  $\times$  3 l, 12 hr),  $\text{Me}_2\text{CO}$  (1  $\times$  3 l, 12 hr) and MeOH (2  $\times$  3 l, 24 hr) in a Soxhlet apparatus. The ether (27.23 g) and EtOAc (2.13 g) extracts did not contain phenolic substances ( $\text{AgNO}_3$  and benzidine spray reagents on 2D paper chromatograms) and were not further investigated. A portion (11.3 g) of the acetone extract (18.4 g) was chromatographed on Sephadex LH-20 in EtOH to give fractions A (3.3 g, *RR*, 55.4 hr), B (1.27 g, *RR*, 70.9 hr), C (0.99 g, *RR*, 87.2 hr) and D (4.06 g, *RR*, 113.9 hr). Rechromatography [silica gel,  $\text{CHCl}_3$ -MeOH (3:1)] of fraction A afforded fractions Aa (2.46 g, *RR*, 19.4 hr) and Ab (346 mg, *RR*, 42.7 hr). The Aa fraction consisted of harpagoside and the Ab fraction of procumbide.

A portion (700 mg) of fraction B was separated by prep. TLC in  $\text{CHCl}_3$ -EtOH (2:1) to give two bands at  $R_f$  0.50 (18 mg) and 0.33 (278 mg). The  $R_f$  0.50 fraction afforded 6'-*O*-*p*-coumaroyl procumbide [15] as an amorphous solid.

The  $R_f$  0.33 band afforded  $\beta$ -(3',4'-dihydroxyphenyl) ethyl-*O*- $\alpha$ -L-rhamnopyranosyl(1  $\rightarrow$  3)- $\beta$ -D-glucopyranoside 6 as an amorphous solid;  $^1\text{H}$  NMR (80 MHz, acetone- $d_6$ ):  $\delta$ 6.80 (1H, *d*,  $J$

Table 2.  $^{13}\text{C}$ NMR (75.432 MHz) peaks (ppm) of phenolic glycoside methyl ether acetates 2, 4 and 7 in  $\text{CDCl}_3$ 

	C	Acteoside 2	Isoacteoside 4	Bioside 7
Glucosyl	1	100.78	100.92	100.86
	2	72.24	71.56	71.44
	3*	80.41	81.62	81.56
	4	69.22	69.69	69.48
	5	72.03	72.07	71.93
	6	62.33	62.14	62.05
Rhamnosyl	1'	98.88	99.54	99.48
	2'	70.08	69.83	69.79
	3'	68.47	68.75	68.73
	4'	70.69	70.54	70.49
	5'	67.14	67.47	67.45
	6'	17.55	17.32	17.27
Phenethyl	$\alpha$	70.69	70.80	70.76
	$\beta$	35.63	35.69	35.63
	1"	131.01	130.97	130.99
	2"	112.33	112.33	112.33
	3"†	148.55	148.59	148.57
	4"†	147.32	147.35	147.33
	5"	111.04	111.07	111.04
	6"	120.64	120.68	120.65
	CO	165.32	166.71	
	$\alpha$	114.22	114.92	
<i>t</i> -Caffeoyl	$\beta$	146.21	145.39	
	1"	126.77	127.14	
	2"	109.54	109.49	
	3"‡	151.35	151.12	
	4"‡	149.08	149.07	
	5"	110.92	110.87	
	6"	122.76	122.88	
	OMe	55.85 ( $\times 4$ )	55.89 ( $\times 4$ )	55.85 ( $\times 2$ )
	OCOCH <sub>3</sub>	20.90, 20.86, 20.65 ( $\times 3$ )	21.17, 20.99, 20.85, 20.69 ( $\times 2$ )	21.11, 20.96, 20.84 ( $\times 2$ ), 20.65
	OCOCH <sub>3</sub>	170.61, 169.82 ( $\times 2$ )	170.02, 169.89, 169.42,	170.65, 170.00, 169.88,
		169.32, 169.19	169.31, 169.26	169.39, 169.25 ( $\times 2$ )

\*Distinguished by means of single frequency heteronuclear decoupling of the 6'-methyl protons leading to pronounced sharpening of the 5'-C.

†The shifts for the C-3" and C-4" resonances may be reversed.

‡The shifts for the C-3" and C-4" resonances may be reversed.


= 1.8 Hz, H-2"), 6.75 (1H, *d*,  $J$  = 8.25 Hz, H-5"), 6.58 (1H, *dd*,  $J$  = 1.8, 8.25 Hz, H-6"), 5.20 (1H, *br s*, H-1'), 4.38 (1H, *d*,  $J$  = 7.5 Hz, H-1), 4.25–3.00 (12H, *m*, H-glycosidic + CH<sub>2</sub>- $\alpha$ ), 2.64 (2H, *t*,  $J$  = 7.25 Hz, H- $\beta$ ), and 1.23 (3H, *d*,  $J$  = 7.5 Hz, CH<sub>3</sub>-6'). The bioside 6 (111 mg) was successively methylated and acetylated. Prep. TLC in hexane–Me<sub>2</sub>CO–EtOAc (11:6:3) afforded the di-*O*-methyl hexa-*O*-acetyl derivative 7 (80 mg,  $R_f$  0.36) of the bioside as a light yellow solid (found: C, 54.8; H, 6.0; C<sub>34</sub>H<sub>46</sub>O<sub>18</sub> requires: C, 55.0; H, 6.3%);  $^1\text{H}$  and  $^{13}\text{C}$  NMR (Tables 1 and 2, resp.); CD (*c* 0.0892):  $[\theta]_{280}^0$ ,  $[\theta]_{260}^0$  5400,  $[\theta]_{240}^0$  4400, and  $[\theta]_{230}^0$  0.

Fraction C consisted of a mixture of the compounds in fractions B and D and was not further investigated.

Separation of fraction D (4.06 g) by PC (2% aq. HOAc) gave two bands at  $R_f$  0.63 (1.14 g) and 0.39 (2.19 g). The  $R_f$  0.63 fraction gave  $\beta$ -(3',4'-dihydroxyphenyl)ethyl-*O*- $\alpha$ -L-rhamnopyranosyl(1  $\rightarrow$  3)- $\beta$ -D-4-(*O*-caffeoyl)glucopyranoside 1 (acteoside) as a solid.  $^1\text{H}$  NMR (80 MHz, acetone-*d*<sub>6</sub>):  $\delta$  7.63 [1H, *d*,  $J$  = 16.0 Hz, H- $\beta$ (vinyl)], 7.28–6.50 (6H, *m*, aromatic), 6.33 [1H, *d*,  $J$  = 16.0 Hz, H- $\alpha$ (vinyl)], 5.31 (1H, *s*, H-1'), 5.19–3.27 (13H, *m*, H-glycosidic + CH<sub>2</sub>- $\alpha$ ), 2.63 (2H, *t*,  $J$  = 6.25 Hz, CH<sub>2</sub>- $\beta$ ),

and 1.08 (3H, *d*,  $J$  = 6.25 Hz, CH<sub>3</sub>-6'). Acteoside 1 (215 mg) was methylated and the mixture separated by prep. TLC in CHCl<sub>3</sub>–EtOH (2:1) to give a band at  $R_f$  0.25 (121 mg). A portion (90 mg) of this fraction was acetylated and subsequently separated by prep. TLC in hexane–Me<sub>2</sub>CO–EtOAc (12:3:5) to give the tetra-*O*-methyl penta-*O*-acetyl derivative 2 (90 mg,  $R_f$  0.21) as an amorphous solid (found: C, 57.9; H, 6.0; calc. for C<sub>43</sub>H<sub>54</sub>O<sub>20</sub>: C, 58.0; H, 6.1%);  $^1\text{H}$  and  $^{13}\text{C}$  NMR (Tables 1 and 2); CD (*c* 0.1412):  $[\theta]_{369}^0$ ,  $[\theta]_{318}^0$  –788 700,  $[\theta]_{305}^0$  –649 900,  $[\theta]_{290}^0$  –750 800,  $[\theta]_{260}^0$  –107 300, and  $[\theta]_{233}^0$  0.

The  $R_f$  0.39 fraction afforded  $\beta$ -(3',4'-dihydroxyphenyl)ethyl-*O*- $\alpha$ -L-rhamnopyranosyl(1  $\rightarrow$  3)- $\beta$ -D-(6-*O*-caffeoyl)glucopyranoside 3 (isoacteoside) as an amorphous solid;  $^1\text{H}$  NMR (80 MHz, acetone-*d*<sub>6</sub>):  $\delta$  7.55 [1H, *d*,  $J$  = 16.0 Hz, H- $\beta$ (vinyl)], 7.19–6.42 (6H, *m*, aromatic), 6.28 [1H, *d*,  $J$  = 16.0 Hz, H- $\alpha$ (vinyl)], 5.90–3.28 (13H, *m*, H-glycosidic + CH<sub>2</sub>- $\alpha$ ), 5.20 (1, *br s*, H-1'), 2.70 (2H, *t*,  $J$  = 6.25 Hz, CH<sub>2</sub>- $\beta$ ), and 1.20 (3H, *d*,  $J$  = 6.25 Hz, CH<sub>3</sub>-6'). Methylation of isoacteoside 3 (200 mg) followed by prep. TLC in C<sub>6</sub>H<sub>6</sub>–Me<sub>2</sub>CO–MeOH (6:3:1) gave the tetra-*O*-methyl ether 5 (161 mg,  $R_f$  0.32) which on acetylation (50 mg) and prep. TLC in C<sub>6</sub>H<sub>6</sub>–Me<sub>2</sub>CO (4:1  $\times$  2) afforded the



Reagents: (i)  $(\text{CH}_3)_2\text{CO}-\text{ZnCl}_2-\text{H}_3\text{PO}_4$ ; (ii)  $\text{BzCl}-\text{KOH}$ ; (iii)  $\text{MeOH}-1\text{M H}_2\text{SO}_4$ ; (iv)  $\text{Ac}_2\text{O}-\text{pyridine}$ ; (v)  $\text{HBr}-\text{HOAc}$ ; (vi)  $\beta-(3,4\text{-dimethoxyphenyl})\text{ethanol}-\text{Ag}_2\text{O}-\text{CaSO}_4\text{-dry CHCl}_3$ ; (vii)  $\text{H}_2-\text{Pd/C}$ ; (viii)  $\text{HgBr}_2\text{-Hg(CN)}_2\text{-dry CH}_3\text{CN}$

Scheme 1.

tetra-*O*-methyl penta-*O*-acetyl derivative 4 (30 mg,  $R_f$  0.35) as an amorphous solid (found: C, 57.8; H, 5.9;  $\text{C}_{43}\text{H}_{54}\text{O}_{20}$  requires: C, 58.0; H, 6.1%);  $^1\text{H}$  and  $^{13}\text{C}$  NMR (Tables 1 and 2, resp.); CD ( $c$  0.1412):  $[\theta]_{358}^{\text{D}}$  0,  $[\theta]_{321}^{\text{D}}$  17 000,  $[\theta]_{300}^{\text{D}}$  10 700,  $[\theta]_{290}^{\text{D}}$  13 900, and  $[\theta]_{250}^{\text{D}}$  0.

**Alkaline hydrolysis of isoacteoside 5.** The tetra-*O*-methyl ether of isoacteoside 5 (84.6 mg) was stirred in a 0.5% solution of NaOMe in MeOH (5 ml) at room temp. for 1 hr. The solvent was evaporated and the mixture resolved by prep. TLC in  $\text{C}_6\text{H}_6\text{-Me}_2\text{CO}$  (7:3) to give two bands at  $R_f$  0.75 (4.2 mg) and 0.25 (46.5 mg). The former fraction afforded methyl-(3,4-di-*O*-methyl)caffeate as a brown solid. Acetylation of the  $R_f$  0.25 band gave the tetramethyl hexa-*O*-acetyl derivative 7 (59.2 mg) of the bioside 6, identical to that of the natural product [ $^1\text{H}$  NMR (Table 1)].

**Synthesis of the methyl ether acetate 7 of the bioside 6.**  $\alpha\text{-D}$ -Glucose (40.5 g) was converted into the 1:2,5:6-di-*O*-isopropylidene derivative 9 (20.5 g, mp 110–111° [from  $\text{CHCl}_3\text{-hexane}$  (2:1)], lit. [24] mp 105–109°) according to the standard lit. [24] procedure. This derivative (5 g), benzyl chloride (24.4 g), and KOH (16.2 g) was heated at 130–150° for 2 hr. The mixture was cooled, diluted with  $\text{H}_2\text{O}$  (100 ml) and extracted with  $\text{CHCl}_3$  (5  $\times$  100 ml). The combined extract was washed with  $\text{H}_2\text{O}$  (5  $\times$  200 ml), dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to dryness. CC [silica gel;  $\text{C}_6\text{H}_6\text{-Me}_2\text{CO}$  (9:1)] afforded the 3-*O*-benzyl analogue [25, 26] 10 (6.41 g) as a light yellow viscous syrup.  $^1\text{H}$  NMR (80 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.32 (5H, s, aromatic), 5.90 (1H, d,  $J = 4.25$  Hz, 1-H), 4.66 (2H, s,  $\text{CH}_2$ ), 4.57 (1H, d,  $J = 4.25$  Hz, H-2), 4.50–3.88 (4H, m, H-3,4,5,6), and 1.49, 1.42, 1.38, 1.29 (12H, 4  $\times$  s, 4  $\times$  Me). The 3-*O*-benzyl-di-*O*-isopropylidene- $\alpha\text{-D}$ -glucose

10 (10 g) was refluxed for 4 hr in MeOH (20 ml) containing 1 M  $\text{H}_2\text{SO}_4$  (10 ml) [27]. The mixture was neutralized with 5%  $\text{NaHCO}_3$  solution and evaporated to dryness. The residue was dissolved in dry MeOH, filtrated and the MeOH removed under red. press. Acetylation followed by prep. TLC in hexane- $\text{C}_6\text{H}_6\text{-Me}_2\text{CO}$  (13:4:3) afforded an anomeric mixture (45%  $\alpha$ :55%  $\beta$ ) of the 3-*O*-benzyl-tetra-*O*-acetyl glucopyranoside 11 (6.57 g,  $R_f$  0.20),  $^1\text{H}$  NMR (80 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.30 [1H, d,  $J = 3.75$  Hz, H-1 ( $\alpha$ -anomer)], and 5.63 [1H, d,  $J = 8.25$  Hz, H-1 ( $\beta$ -anomer)]. This mixture (2.01 g) was reacted for 30 min at 0° with a satd soln of HBr in HOAc (40 ml) [30]. After a further 2 hr at room temp., the mixture was poured into ice/ $\text{H}_2\text{O}$  (500 ml) and extracted with  $\text{CHCl}_3$  (3  $\times$  100 ml). The  $\text{CHCl}_3$  was dried ( $\text{Na}_2\text{SO}_4$ ,  $\times$  2) and removed under reduced pressure at 35°. CC [silica gel; hexane- $\text{Me}_2\text{CO-EtOAc}$  (11:6:3)] afforded 2,4,6-tri-*O*-acetyl-3-*O*-benzyl-1-bromo- $\alpha\text{-D}$ -glucopyranoside 12 as a yellow oil.

A solution of the 1-bromo- $\alpha\text{-D}$ -glucopyranoside 12 (993 mg) in dry alcohol-free  $\text{CHCl}_3$  (20 ml) was added dropwise over a period of 1 hr in the dark to a stirred mixture of  $\beta$ -(3,4-dimethoxyphenyl)ethanol\* (304 mg), freshly prepared silver oxide (700 mg) and dry  $\text{CaSO}_4$  (2 g) in dry alcohol-free  $\text{CHCl}_3$  (30 ml)† [31]. The mixture was filtered and the solvent removed under red. press. at 60°. Prep. TLC in hexane- $\text{Me}_2\text{CO-EtOAc}$  (11:6:3) afforded 2,4,6-tri-*O*-acetyl-3-*O*-benzyl- $\beta$ -(3',4'-dimethoxyphenyl)ethyl- $\beta\text{-D}$ -glucopyranoside 13 as an amorphous solid (590 mg,  $R_f$  0.43) (found:  $M^+$ , 560.4219;  $\text{C}_{29}\text{H}_{36}\text{O}_{11}$  requires:  $M^+$ , 560.2258);  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.35–7.18 (5H, m, H-aromatic), 6.78 (1H, d,  $J = 8.5$  Hz, H-5'), 6.73 (1H, d,  $J = 1.5$  Hz, H-2'), 6.73 (1H, dd,  $J = 1.5, 8.5$  Hz, H-6'), 5.12 (1H, t,  $J = 9.5$  Hz, H-4), 5.05 (1H, dd,  $J = 8.0, 9.5$  Hz, H-2), 4.57 (2H, s,  $\text{Ar-CH}_2$ ), 4.38 (1H, d,  $J = 8.0$  Hz, H-1), 4.22 (1H, dd,  $J = 4.5, 12.5$  Hz, H-6), 4.11 (1H, dd,  $J = 2.5, 12.5$  Hz, H-6), 4.09 (1H, m, H- $\alpha$ ), 3.87, 3.85 (6H, each s, 2  $\times$  OMe), 3.63 (1H, t,  $J = 9.5$  Hz, H-3), 3.59 (2H, m, H-5,  $\alpha$ ), 2.82 (2H, t,  $J = 6.5$  Hz,  $\text{CH}_2\text{-}\beta$ ), and 2.09, 1.98, 1.86 (9H, each s, 3  $\times$  OAc).

\* Prepared by successive esterification ( $\text{MeOH-conc. H}_2\text{SO}_4$ ), methylation ( $\text{Me}_2\text{SO}_4\text{-K}_2\text{CO}_3\text{-Me}_2\text{CO}$ ) and  $\text{LiAlH}_4$  reduction of 3,4-dihydroxyphenylacetic acid.

† Mixture pre-stirred in the dark for 1 hr.

The 3-*O*-benzyl- $\beta$ -D-glucopyranoside **13** (207 mg) was hydrogenated (10% Pd-C, 100 mg) in EtOH (50 ml) under ambient conditions. The suspension was filtered and the solvent evaporated to give 2,4,6-tri-*O*-acetyl- $\beta$ -(3',4'-dimethoxyphenyl)ethyl- $\beta$ -D-glucopyranoside **14** (156 mg,  $R_f$  0.25 as an amorphous solid (found:  $M^+$ , 470.2564;  $C_{22}H_{30}O_{11}$  requires:  $M^+$ , 470.1788);  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  6.79 (1H, *d*,  $J$  = 8.5 Hz, H-5'), 6.74 (1H, *dd*,  $J$  = 1.5, 8.5 Hz, H-6'), 6.73 (1H, *d*,  $J$  = 1.5 Hz, H-2'), 4.93 (1H, *t*,  $J$  = 9.5 Hz, H-4), 4.86 (1H, *dd*,  $J$  = 8.0, 9.5 Hz, H-2), 4.43 (1H, *d*,  $J$  = 8.0 Hz, H-1), 4.30 (1H, *dd*,  $J$  = 4.5, 12.5 Hz, H-6), 4.15 (1H, *dd*,  $J$  = 2.5, 12.5 Hz, H-6), 4.10 (1H, *dt*,  $J$  = 6.5, 9.5 Hz, H- $\alpha$ ), 3.89, 3.86 (6H, each *s*,  $2 \times$  OMe), 3.74–3.58 (3H, *m*, H-3,5, $\alpha$ ), 2.84 (2H, *t*,  $J$  = 6.5 Hz,  $CH_2$ - $\beta$ ), 2.60 (1H, *d*,  $J$  = 6.5 Hz, 3-OH), and 2.13, 2.09, 2.00 (9H, each *s*,  $3 \times$  OAc).

Tetra-*O*-acetyl- $\alpha$ -L-rhamnopyranoside (2.5 g) was converted to 2,3,4-tri-*O*-acetyl-1-bromo- $\alpha$ -L-rhamnopyranoside **15** (ca 2.06 g) by means of HBr in HOAc [30]. A portion (150 mg) of this bromo derivative in dry acetonitrile (5 ml) was immediately added to a solution of 2,4,6-tri-*O*-acetyl- $\beta$ -(3',4'-dimethoxyphenyl)ethyl- $\beta$ -D-glucopyranoside **14** (33.7 mg),  $HgBr_2$  (40 mg), and  $Hg(CN)_2$  (30 mg) in dry acetonitrile (20 ml) and the mixture stirred at room temp. for 24 hr. After removal of the acetonitrile under red. pres. at 60°,  $CHCl_3$  was added and the precipitated mercury salts filtered off. The organic phase was extracted with 1 M KBr soln ( $3 \times 50$  ml), washed with  $H_2O$  ( $2 \times 100$  ml), dried ( $Na_2SO_4$ ), and evaporated to dryness. Due to partial de-acetylation, the mixture was acetylated and subsequently resolved by prep. TLC in hexane- $Me_2CO$ -EtOAc (11:6:3) to afford the phenolic *O*-methyl ether hexa-*O*-acetyl derivative **7** (9.8 mg,  $R_f$  0.40) of the bioside **6**, identical [ $^1H$  NMR (Table 1) and CD] to that obtained from the secondary roots of *H. procumbens*.

**Acknowledgements**—Support by the Foundation for Research Development, C.S.I.R., Pretoria and the Sentrale Navorsingsfonds of this University is gratefully acknowledged. Dried roots of *H. procumbens* were supplied by S. W. A. Teufelskralle Exporters (Pty) Ltd., P.O. Box 34, Windhoek, Namibia. One of us (J.F.W.B.) is the recipient of a C.S.I.R. scholarship.

## REFERENCES

- Watt, J. M. and Breyer-Brandwijk, M. G. (1962) *The Medicinal and Poisonous Plants of Southern and Eastern Africa*, 2nd Ed, p. 830. E. & S. Livingstone, London.
- Carston, R. (1980) in *Devil's Claw Root and Other Natural Remedies for Arthritis*. Alive Books, Vancouver.
- Ziller, K. H. and Franz, G. (1979) *Planta Med.* **37**, 340.
- Von Sticher, O. (1977) *Dtsch. Apoth. Ztg.* **117**, 1279.
- Bianco, A., Esposito, P., Gwiso, M. and Scarpati, M. L. (1971) *Gazz. Chim. Ital.* **101**, 764.
- Czygan, F.-C., Krüger, A., Schier, W. and Volk, O. H. (1977) *Dtsch. Apoth. Ztg.* **117**, 143.
- Erdös, A., Fontaine, R., Friche, H., Durand, R. and Pöppinghaus, Th. (1978) *Planta Med.* **34**, 97.
- Tunmann, P. and Lux, R. (1962) *Dtsch. Apoth. Ztg.* **102**, 1274.
- Lichti, H. and Von Wartburg, A. (1964) *Tetrahedron Letters* **835**.
- Lichti, H. and Von Wartburg, A. (1966) *Helv. Chim. Acta* **49**, 1552.
- Tunmann, P. and Stierstorfer, N. (1963) *Dtsch. Apoth. Ztg.* **105**, 395.
- Tunmann, P. and Stierstorfer, N. (1964) *Tetrahedron Letters* **1697**.
- Tunmann, P. and Hammer, H. E. (1968) *Justus Liebigs Ann. Chem.* **712**, 138.
- Bendall, M. R., Ford, C. W. and Thomas, D. M. (1979) *Austr. J. Chem.* **32**, 2085.
- Kikuchi, T., Matsuda, A., Kubo, Y. and Namba, T. (1983) *Chem. Pharm. Bull.* **31**, 2296.
- Birkofer, L., Kaiser, C. and Thomas, U. (1968) *Z. Naturforsch. Teil C* **23b**, 1051.
- Nonaka, G. and Nishioka, I. (1977) *Phytochemistry* **16**, 1265.
- Cooper, R., Solomon, P. H., Kubo, I., Nakanishi, K., Shoolery, J. N. and Occolowitz, J. L. (1980) *J. Am. Chem. Soc.* **102**, 7955.
- Scarpati, M. L. and Monache, D. (1963) *Am. Chim. (Rome)* **53**, 356.
- Andary, C., Wylde, R., Laffite, C., Privat, G. and Winternitz, F. (1982) *Phytochemistry* **21**, 1123.
- Sakurai, A. and Kato, T. (1983) *Bull. Chem. Soc. Japan* **56**, 1573.
- Miyase, T., Koizuma, A., Ueno, A., Noro, T., Kuroyanagi, M., Fukushima, S., Akiyama, Y. and Takemoto, T. (1982) *Chem. Pharm. Bull.* **30**, 2732.
- Lloyd, K. and Hornykiewicz, O. (1970) *Science* **170**, 1212.
- Glen, W. L., Myers, G. S., and Grant, G. A. (1951) *J. Chem. Soc.* **2568**.
- Fletcher, H. G. (1962) in *Methods in Carbohydrate Chemistry* (Whistler, R. L. and Wolfrom, M. L., eds) Vol. II, p. 166. Academic Press, London.
- McCloskey, C. M. (1957) *Adv. Carbohydr. Chem.* **12**, 137.
- Freudenberger, K., Von Hochstetter, H. and Engels, K. (1925) *Chem. Ber.* **58**, 666.
- Wulff, G. and Röhle, G. (1974) *Angew. Chem. Int. Ed. Engl.* **13**, 157.
- Paulson, H. (1984) *Chem. Soc. Rev.* **13**, 15.
- Fischer, E., Bergmann, M. and Rabe, A. (1920) *Chem. Ber.* **53**, 2362.
- Reynolds, D. and Evans, L. (1938) *J. Am. Chem. Soc.* **60**, 2559.